2 results
Approved WMOPending
The primary efficacy objective for this study is to demonstrate non-inferiority of ocrelizumab compared with fingolimod
Approved WMOPending
To prospectively investigate if a treatment strategy in which two types of cytotoxic RLT, i.e., an alpha-emitter and a beta-emitter, are alternatively offered to patients with oligometastatic HSPCa, is feasible and safe